Literature DB >> 27127302

Protease-activated receptors in hemostasis.

Marvin T Nieman1.   

Abstract

Protease signaling in cells elicits multiple physiologically important responses via protease-activated receptors (PARs). There are 4 members of this family of G-protein-coupled receptors (PAR1-4). PARs are activated by proteolysis of the N terminus to reveal a tethered ligand. The rate-limiting step of PAR signaling is determined by the efficiency of proteolysis of the N terminus, which is regulated by allosteric binding sites, cofactors, membrane localization, and receptor dimerization. This ultimately controls the initiation of PAR signaling. In addition, these factors also control the cellular response by directing signaling toward G-protein or β-arrestin pathways. PAR1 signaling on endothelial cells is controlled by the activating protease and heterodimerization with PAR2 or PAR3. As a consequence, the genetic and epigenetic control of PARs and their cofactors in physiologic and pathophysiologic conditions have the potential to influence cellular behavior. Recent studies have uncovered polymorphisms that result in PAR4 sequence variants with altered reactivity that interact to influence platelet response. This further demonstrates how interactions within the plasma membrane can control the physiological output. Understanding the structural rearrangement following PAR activation and how PARs are allosterically controlled within the plasma membrane will determine how best to target this family of receptors therapeutically. The purpose of this article is to review how signaling from PARs is influenced by alternative cleavage sites and the physical interactions within the membrane. Going forward, it will be important to relate the altered signaling to the molecular arrangement of PARs in the cell membrane and to determine how these may be influenced genetically.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27127302      PMCID: PMC4946198          DOI: 10.1182/blood-2015-11-636472

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  122 in total

Review 1.  Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development.

Authors:  Katie O'Callaghan; Athan Kuliopulos; Lidija Covic
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

2.  Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization.

Authors:  Joseph N McLaughlin; Myla M Patterson; Asrar B Malik
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-21       Impact factor: 11.205

3.  Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.

Authors:  Andrew J Leger; Suzanne L Jacques; Jehangir Badar; Nicole C Kaneider; Claudia K Derian; Patricia Andrade-Gordon; Lidija Covic; Athan Kuliopulos
Journal:  Circulation       Date:  2006-02-27       Impact factor: 29.690

Review 4.  Matrix metalloproteinase inhibition. From the Jurassic to the third millennium.

Authors:  J F Woessner
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

5.  Protease-activated receptor 3 is a second thrombin receptor in humans.

Authors:  H Ishihara; A J Connolly; D Zeng; M L Kahn; Y W Zheng; C Timmons; T Tram; S R Coughlin
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

6.  Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome.

Authors:  Emily S Wan; Weiliang Qiu; Andrea Baccarelli; Vincent J Carey; Helene Bacherman; Stephen I Rennard; Alvar Agusti; Wayne Anderson; David A Lomas; Dawn L Demeo
Journal:  Hum Mol Genet       Date:  2012-04-06       Impact factor: 6.150

7.  Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation.

Authors:  Clemens Feistritzer; Matthias Riewald
Journal:  Blood       Date:  2004-12-30       Impact factor: 22.113

8.  Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer.

Authors:  Matthew R Whorton; Beata Jastrzebska; Paul S-H Park; Dimitrios Fotiadis; Andreas Engel; Krzysztof Palczewski; Roger K Sunahara
Journal:  J Biol Chem       Date:  2007-11-22       Impact factor: 5.157

9.  'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage.

Authors:  Nicole C Kaneider; Andrew J Leger; Anika Agarwal; Nga Nguyen; George Perides; Claudia Derian; Lidija Covic; Athan Kuliopulos
Journal:  Nat Immunol       Date:  2007-10-28       Impact factor: 25.606

10.  Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking.

Authors:  Natalie S Shenker; Silvia Polidoro; Karin van Veldhoven; Carlotta Sacerdote; Fulvio Ricceri; Mark A Birrell; Maria G Belvisi; Robert Brown; Paolo Vineis; James M Flanagan
Journal:  Hum Mol Genet       Date:  2012-11-21       Impact factor: 6.150

View more
  37 in total

1.  Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo.

Authors:  Laura D Healy; Cristina Puy; José A Fernández; Annachiara Mitrugno; Ravi S Keshari; Nyiawung A Taku; Tiffany T Chu; Xiao Xu; András Gruber; Florea Lupu; John H Griffin; Owen J T McCarty
Journal:  J Biol Chem       Date:  2017-04-13       Impact factor: 5.157

Review 2.  Activated protein C in neuroprotection and malaria.

Authors:  Laurent O Mosnier
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

Review 3.  Therapeutic strategies for thrombosis: new targets and approaches.

Authors:  Nigel Mackman; Wolfgang Bergmeier; George A Stouffer; Jeffrey I Weitz
Journal:  Nat Rev Drug Discov       Date:  2020-03-04       Impact factor: 84.694

Review 4.  The domino effect triggered by the tethered ligand of the protease activated receptors.

Authors:  Xu Han; Marvin T Nieman
Journal:  Thromb Res       Date:  2020-08-04       Impact factor: 3.944

Review 5.  Targeting PAR1: Now What?

Authors:  Robert Flaumenhaft; Karen De Ceunynck
Journal:  Trends Pharmacol Sci       Date:  2017-05-27       Impact factor: 14.819

6.  Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.

Authors:  Madhavi A Jadhav; Whitney N Goldsberry; Sara E Zink; Kelsey N Lamb; Katelyn E Simmons; Carmela M Riposo; Boris A Anokhin; Muriel C Maurer
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2017-07-04       Impact factor: 3.036

Review 7.  The immunopathology of sepsis and potential therapeutic targets.

Authors:  Tom van der Poll; Frank L van de Veerdonk; Brendon P Scicluna; Mihai G Netea
Journal:  Nat Rev Immunol       Date:  2017-04-24       Impact factor: 53.106

8.  GRK6 regulates the hemostatic response to injury through its rate-limiting effects on GPCR signaling in platelets.

Authors:  Xi Chen; Shuchi Gupta; Matthew Cooper; Daniel DeHelian; Xuefei Zhao; Meghna U Naik; Jeremy G T Wurtzel; Timothy J Stalker; Lawrence E Goldfinger; Jeffrey Benovic; Lawrence F Brass; Steven E McKenzie; Ulhas P Naik; Peisong Ma
Journal:  Blood Adv       Date:  2020-01-14

9.  A thrombin-PAR1/2 feedback loop amplifies thromboinflammatory endothelial responses to the viral RNA analogue poly(I:C).

Authors:  Saravanan Subramaniam; Yamini Ogoti; Irene Hernandez; Mark Zogg; Fady Botros; Robert Burns; Jacob T DeRousse; Chris Dockendorff; Nigel Mackman; Silvio Antoniak; Craig Fletcher; Hartmut Weiler
Journal:  Blood Adv       Date:  2021-07-13

Review 10.  Mouse models of hemostasis.

Authors:  Bassem M Mohammed; Dougald M Monroe; David Gailani
Journal:  Platelets       Date:  2020-01-28       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.